This review highlights the pharmacological potential of Angiotensin-(1-7) as a therapeutic agent for various cardiovascular and non-cardiovascular diseases.
Angiotensin-(1-7) warrants no immediate clinical adoption; leaves open prospective trials to validate its protective effects.
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
No takes yet. Share an insight, caveat, or question.
Trask et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: